A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

View/Open

Supporting information (63.31Kb)

Date

2018-08

ICR Author

Marsden,

Yap, Christina

Author

Pratt, G

Yap, C

Oldreive, C

Slade, D

Bishop, R

Griffiths, M

Dyer, MJS

Fegan, C

Oscier, D

Pettitt, A

Matutes, E

Devereux, S

Allsup, D

Bloor, A

Hillmen, P

Follows, G

Rule, S

Moss, P

Stankovic, T

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/1518

DOI

https://doi.org/10.1111/bjh.14793

Collections

• Clinical Studies

Subject

Humans

Lymphoma, Mantle-Cell

Lymphoproliferative Disorders

DNA Damage

Recurrence

Piperazines

Phthalazines

Survival Analysis

Maximum Tolerated Dose

Aged

Middle Aged

Female

Male

Tumor Suppressor Protein p53

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Prolymphocytic, T-Cell

Ataxia Telangiectasia Mutated Proteins

Poly(ADP-ribose) Polymerase Inhibitors

Research team

Clinical Trials & Statistics Unit

Language

eng

License start date

2018-08

Citation

British journal of haematology, 2018, 182 (3), pp. 429 - 433